Viral escape mutations do not account for non-protection from SIVmac239 challenge in RhCMV/SIV vaccinated rhesus macaques.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 05 06 2024
accepted: 17 07 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: epublish

Résumé

Simian immunodeficiency virus (SIV) vaccines based upon 68-1 Rhesus Cytomegalovirus (RhCMV) vectors show remarkable protection against pathogenic SIVmac239 challenge. Across multiple independent rhesus macaque (RM) challenge studies, nearly 60% of vaccinated RM show early, complete arrest of SIVmac239 replication after effective challenge, whereas the remainder show progressive infection similar to controls. Here, we performed viral sequencing to determine whether the failure to control viral replication in non-protected RMs is associated with the acquisition of viral escape mutations. While low level viral mutations accumulated in all animals by 28 days-post-challenge, which is after the establishment of viral control in protected animals, the dominant circulating virus in virtually all unprotected RMs was nearly identical to the challenge stock, and there was no difference in mutation patterns between this cohort and unvaccinated controls. These data definitively demonstrate that viral mutation does not explain lack of viral control in RMs not protected by RhCMV/SIV vaccination. We further demonstrate that during chronic infection RhCMV/SIV vaccinated RMs do not acquire escape mutation in epitopes targeted by RhCMV/SIV, but instead display mutation in canonical MHC-Ia epitopes similar to unvaccinated RMs. This suggests that after the initial failure of viral control, unconventional T cell responses induced by 68-1 RhCMV/SIV vaccination do not exert strong selective pressure on systemically replicating SIV.

Identifiants

pubmed: 39170621
doi: 10.3389/fimmu.2024.1444621
pmc: PMC11336698
doi:

Substances chimiques

SAIDS Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1444621

Informations de copyright

Copyright © 2024 Bimber, Sunshine, McElfresh, Reed, Pathak, Bateman, Hughes, Gilbride, Ford, Morrow, Lifson, Sacha, Hansen and Picker.

Déclaration de conflit d'intérêts

Oregon Health & Science University (OHSU), LP, JS, BB, and SH have a substantial financial interest in Vir Biotechnology Inc., a company that may have a commercial interest in the results of this research and technology. LP, and SH have received compensation for consulting for Vir. The potential individual and institutional conflicts of interest have been reviewed and managed by OHSU. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Benjamin N Bimber (BN)

Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

Justine Sunshine (J)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

G W McElfresh (GW)

Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.

Jason S Reed (JS)

Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.

Reese Pathak (R)

Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.

Katherine B Bateman (KB)

Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.

Colette M Hughes (CM)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

Roxanne M Gilbride (RM)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

Julia C Ford (JC)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

David Morrow (D)

Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

Jeffrey D Lifson (JD)

AIDS and Cancer Virus Program, Frederick National Laboratory, Frederick, MD, United States.

Jonah B Sacha (JB)

Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

Scott G Hansen (SG)

Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

Louis J Picker (LJ)

Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, United States.
Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR, United States.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH